Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Beam Therapeutics will manufacture precision genetic medicines through the use of base editing technology at its RTP site.

Expanding therapeutic potential with novel Parvovirus gene therapy.

Ceribell is a fast-growing venture-backed medical device start-up company founded by two faculty members at Stanford University. Our primary mission is to improve neurological care for emergency and ICU patients. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The system can be set up by any healthcare provider within minutes. Now with Clarity, Ceribell offers 24/7 continuous bedside EEG monitoring and alert.

Certik is a pioneer in blockchain security, leveraging best-in-class AI technology to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, Certik’s mission is to secure the Web3 world. Certik applies cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness. One of the fastest-growing and most trusted companies in blockchain security, Certik is a true market leader. To date, Certik has worked with nearly 4,000 enterprise clients, secured over $360 billion worth of digital assets, and has detected nearly 70,000 vulnerabilities in blockchain code. Our clients include leading projects such as Aave, Polygon, Binance Smart Chain, Terra, Yearn, and Chiliz. Certik is backed by Insight Partners, Sequoia, Tiger Global, Coatue Management, Lightspeed, Advent International, SoftBank, Hillhouse Capital, Goldman Sachs, and Coinbase Ventures.

CG Oncology, Inc. (NASDAQ: CGON) is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, Cretostimogene Grenadenorepvec, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene Grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with Cretostimogene Grenadenorepvec in combination with OPDIVO® (nivolumab).

Cobo is a trusted leader in digital asset custody and wallet infrastructure solutions. Founded in 2017 by blockchain pioneers, Cobo is trusted by more than 500 organizations worldwide, safeguarding billions of dollars in assets with a zero-incident security track record. Today, Cobo provides the industry’s only unified digital asset wallet platform that integrates all 4 wallet technologies in one place – custodial wallets, MPC wallets, smart contract wallets, and exchange wallets. By combining a comprehensive suite of wallet solutions with advanced risk controls and developer tools, Cobo empowers organizations and developers to innovate and scale with ease.

Cosmos is an ever-expanding ecosystem of interoperable and sovereign blockchain apps and services, built for a decentralized future.

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes. Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with Amnestic Mild Cognitive Impairment (AMCI).

The DFINITY Foundation’s mission is to build, promote, and maintain the Internet Computer — the world’s first web-speed, internet-scale public blockchain. It enables smart contracts to securely serve interactive web content directly into the browsers of end users, making it possible to build dApps, DeFi, open internet services, and enterprise systems that are capable of operating at hyperscale. The Internet Computer uses smart contracts to power an emerging decentralized ecosystem of interoperable dApps and services, where nearly every system and service can run in reimagined form on public blockchain.

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Our passion is to provide Web3 changemakers with the ultimate infrastructure platform to reshape the world.